MYELOFIBROSIS

This early-phase trial tests a new drug (imetelstat) added to standard treatment (ruxolitinib) for people with myelofibrosis, a rare bone marrow cancer. The goal is to find the safest dose and see if the combination improves symptoms like fatigue and pain. About 36 adults with in…

This program offers the investigational drug selinexor to people with multiple myeloma, lymphoma, sarcoma, or other cancers who have run out of approved treatments and cannot join a clinical trial. It is not a cure but aims to control the disease. Patients must get approval from …

This study tests whether giving high doses of ruxolitinib and busulfan before a stem cell transplant can reduce spleen size and improve transplant outcomes in people with myelofibrosis. About 30 adults aged 18 to 75 with an enlarged spleen and a matched donor will take part. The …

This study tests a two-step method using lower doses of radiation and chemotherapy before a stem cell transplant for people with various blood cancers or bone marrow failure. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About…

This study tests the safety of a drug called momelotinib given during and after a stem cell transplant for people with myelofibrosis, a type of bone marrow cancer. About 28 participants will receive the drug to find the highest safe dose. The goal is to control the disease and ma…

This study tests a drug called selinexor in about 58 adults with myelofibrosis (a bone marrow disorder) who have mild to moderate low platelet counts and have not taken JAK inhibitors before. The main goal is to see if selinexor can shrink the spleen by at least 35% after 24 week…

This study is for people with blood cancers like leukemia or lymphoma who need a stem cell transplant from an unrelated donor. It compares two ways to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. One method uses a d…

This study tests an experimental oral drug called LP-118 in up to 100 adults with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to other treatments. The main goals are to find the safest dose and see if the drug can shrink tumors …

This study is for people with blood cancers who need a stem cell transplant from an unrelated donor with a different blood type. The goal is to find which drug combination works best to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the …

This study tests an experimental drug called RVU120 in adults with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. Participants receive RVU120 alone or combined with the standard drug ruxolitinib. The main goal is to see if the drug can shrink the spleen an…

This study tests whether adding navtemadlin to the standard drug ruxolitinib helps people with myelofibrosis who are not getting enough benefit from ruxolitinib alone. About 600 adults with myelofibrosis will first take ruxolitinib, then those with a weak response will be randoml…

This early-phase study tests an experimental drug, JNJ-88549968, designed to help the immune system attack cancer cells with a specific genetic change (CALR mutation). About 220 adults with essential thrombocythemia or myelofibrosis will receive the drug to find a safe dose and c…

This study tests whether combining two experimental drugs (TQ05105 and TQB3617) can safely reduce spleen size and improve symptoms in adults with intermediate- or high-risk myelofibrosis, a type of bone marrow cancer. About 92 participants will receive the combination to find the…

This study tests a new drug called KER-050 (elritercept) in about 135 adults with myelofibrosis, a rare bone marrow cancer. The drug is given alone or with the standard treatment ruxolitinib. The main goals are to check safety and see if it helps with anemia and other symptoms. T…

This early-phase study tests an oral drug called PMD-026 in 18 adults with myelofibrosis, a type of blood cancer. Participants must have already tried a JAK inhibitor without success. The main goals are to check safety, find the right dose, and see if the drug can shrink the sple…

This study tests an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome who also have anemia. The goal is to see if the drug is safe and can help patients need fewer or no blood transfusions. The study is in early to mid stages an…

This study tests whether Nelfinavir, a drug originally used for HIV, can improve anemia in people with myelofibrosis, a rare bone marrow cancer. The drug aims to help the body deliver iron to the bone marrow to make more red blood cells. About 10 adults with low hemoglobin will t…

This study tests an experimental pill called nuvisertib in adults with myelofibrosis, a serious bone marrow disorder. The goal is to see if the drug is safe and can reduce spleen enlargement and other symptoms. Participants must have intermediate or high-risk disease and have alr…

This study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who are already doing well on the drug bomedemstat. It aims to collect long-term safety information and see how well the drug continues to work. About 400 participants will conti…

This study tests a new device that filters excess iron from the blood in people with myelodysplastic syndrome (MDS) or myelofibrosis who cannot take standard iron-removing medications. Participants will undergo three short dialysis-like sessions over one week. The goal is to see …

This study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in adults with blood cancers who are at high risk of rejecting a stem cell transplant. Participants receive the drug before standard transplant preparation to reduce DSA levels enough to al…

This study tests if adding ulixertinib to the standard drug ruxolitinib is safe and works for people with myelofibrosis, a type of bone marrow cancer. About 37 adults who are already on a stable dose of ruxolitinib will join. The goal is to find the best dose of ulixertinib that …

This study is testing whether a special type of PET/MRI scan can accurately diagnose and track myelofibrosis, a serious bone marrow disorder. About 57 adults with the condition will get both a standard PET scan and the new FAPI PET/MRI. The goal is to see if the new scan can matc…

This study tests whether giving a CMV vaccine to stem cell donors can protect transplant recipients from CMV infection. Donors receive the vaccine before donating stem cells, and the immunity is passed to the patient. The trial involves 216 people with blood cancers and aims to r…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after transplant. About 46 people with various blood cancers or disorders will take part. The goal i…

This study tests N-acetylcysteine (N-AC), a supplement, in 27 adults with certain blood cancers (myeloproliferative neoplasms). The goal is to find the best dose that reduces symptoms like fatigue and pain while being safe. Participants continue their usual treatments during the …

This study is testing whether a curcumin supplement (the active ingredient in turmeric) can lower inflammation and improve symptoms in people with certain blood disorders, including low-risk myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). About 30 adults wi…

This study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…

This study follows 617 adults diagnosed with myelofibrosis (a rare bone marrow cancer) across Europe. Researchers will collect routine medical data to see how low blood cell counts at diagnosis affect survival and treatment response. No new treatments are tested; the goal is to l…

This study is a registry that will follow 200 people in Germany with myelofibrosis and anemia. It will collect information on which treatments are used, how well they work, and how patients feel. The goal is to better understand current care and outcomes, not to test a new drug.

This study is testing whether an artificial intelligence tool can help match cancer patients to clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer and use the AI to suggest trials. The goal is to see if this approa…

This study looks at how the drug TQ05105 is handled by the body in people with mild or moderate liver problems compared to healthy volunteers. It involves 24 adults who take a single dose and are monitored for drug levels and safety. The goal is to understand dosing needs, not to…

This study tests a telehealth program to help older patients (60+) with blood cancers like leukemia and MDS communicate better with their doctors and complete advance care plans. About 207 patients and their caregivers will be randomly assigned to the program or usual care. The g…

This study looks at how changes in the ASXL1 gene affect myelofibrosis, a rare bone marrow disorder. Researchers will study 50 adults to find different patterns of these gene changes and see how they relate to patient outcomes. The goal is to better understand the disease and imp…